Adamis Pharmaceuticals (ADMP) stock has risen sharply in the previous five days, but if we look at the dynamics over the last month, we can see that the price has remained very stable and has not risen considerably. The current exchange rate is $1.06.
The United States Food and Drug Administration (FDA) has accepted Adamis Pharmaceuticals’ (NASDAQ: ADMP) re-submitted new drug application (NDA) for ZIMHI TM, a candidate for an injectable medication with a greater naloxone content for the treatment of opioid overdose.
“The FDA’s decision to review our ZIMHI NDA has pleased us. This, I feel, emphasizes the need for more alternative drug overdose treatments “Adamis Pharmaceuticals’ president and CEO, Dr. Dennis J. Carlo, said. “We look forward to engaging with the FDA to assist the ZIMHI approval case during the review process.” However, investors should proceed with caution while investing in this company, as its financial status is predicted to be unstable.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.